BioFinlandin jäsen

Lynsight has developed DiagMMR, a unique predictive diagnostic test to detect Lynch syndrome, the most common inherited cancer predisposition. Unlike current methods requiring tumour tissue, DiagMMR only needs a minute skin biopsy of healthy tissue to detect Lynch syndrome in cancer patients and in healthy individuals alike. This allows for an early diagnosis, enabling cancer prediction and preventive treatment, while unaffected family members can be relieved from regular follow-up.